文献速递肿瘤 PET/CT放射性药物与辐射防护

肺结节病基于体积的18F-FDG PET/CT定量生物标志物的预后意义

Prognostic Implications of Volume-based Quantitative 18F-FDG PET/CT Biomarkers in Pulmonary Sarcoidosis.
PubMed 文献 · Clin Nucl Med · 2025-11-27

本研究从机构登记库选取75例初诊时接受18F-FDG PET/CT的结节病患者,评估基于体积的代谢参数对复合进展终点的预后价值。结果显示进展组基线MVthoracic和MVwhole-body更高,而SUVmax无显著预后关联。MVthoracic和MVwhole-body最佳阈值均为150 cm3,与总体疾病进展相关。

要点

  • 基于体积的MV参数与肺结节病疾病进展相关,而SUVmax无预后意义。
  • MVthoracic和MVwhole-body最佳预后阈值均为150 cm3。
  • MVthoracic>150 vs <150 cm3的OR为1.9(95%CI 1.00-3.49,P=0.049)。

核心结论

  • 基于体积的18F-FDG PET/CT生物标志物与肺结节病疾病进展相关,而SUVmax无预后意义。

研究设计与样本

  • 从机构登记库选取75例初诊时接受18F-FDG PET/CT的结节病患者。
  • 复合进展终点包括FVC下降>5%、DLCO下降>10%、影像学恶化、临床症状加重或死亡。
  • 评估1年、2年和总体疾病进展,计算胸部及胸外病变的MV(SUV阈值2.5)和SUVmax。

主要发现

  • 75例中45例符合进展标准,30例保持缓解。
  • 进展组基线MVthoracic(P=0.002)和MVwhole-body(P<0.001)更高,而全身或器官特异性SUVmax无显著差异。
  • MVthoracic>150 vs <150 cm3的OR为1.9(95%CI 1.00-3.49,P=0.049)。
  • MVwhole-body>150 vs <150 cm3的OR为2.06(95%CI 1.08-3.95,P=0.029)。
  • 总SUVmax或器官特异性SUVmax与进展结局均无显著关联。

关键数值与推荐

  • MVthoracic预测总体疾病进展的最佳阈值为150 cm3。
  • MVwhole-body预测总体疾病进展的最佳阈值也为150 cm3。

临床怎么用

  • 在肺结节病初诊18F-FDG PET/CT中可计算基于体积的MV参数辅助预后评估。
  • MVthoracic或MVwhole-body>150 cm3提示疾病进展风险升高。
  • SUVmax不宜单独用于肺结节病预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcoidosis is a multisystemic granulomatous disease with highly variable manifestations and outcomes, making clinical management challenging. This study evaluated the prognostic value of biomarkers derived from 18F-FDG PET/CT imaging. PATIENTS AND METHODS: From an institutional registry, 75 sarcoidosis patients with a 18F-FDG PET/CT scan performed at the time of initial diagnosis were selected. A composite progression endpoint was defined, comprising either a decrease in FVC>5%, in DLCO>10%, a worsening of radiologic findings, increasing clinical symptoms, or death. Disease progression was assessed by onset at 1 year, 2 years, and overall. The MV of thoracic and extrathoracic lesions attributed to sarcoidosis was calculated, using a SUV threshold of 2.5. SUVmax was also determined for these regions. RESULTS: Of 75 patients, 45 patients met the progression criteria while 30 patients remained in remission. Baseline MVthoracic (P = 0.002) and MVwhole-body (P < 0.001) were higher in patients subsequently showing progression, while no significant differences were observed in whole-body or organ-specific SUVmax. The optimum threshold of MVthoracic for prognosis of overall disease progression was determined at 150 cm3, yielding an OR of 1.9 in the univariate analysis (MVthoracic >150 vs <150 cm3; 95% CI: 1.00-3.49; P = 0.049). For MVwhole-body, the optimal cutoff value was also determined at 150 cm3, with an OR of 2.06 (MVwhole body >150vs <150 cm3; 95% CI: 1.08-3.95; P = 0.029). Neither total nor organ-specific SUVmax had significant associations with progression outcomes. CONCLUSIONS: Volume-based biomarkers derived from 18F-FDG PET/CT were associated with disease progression in pulmonary sarcoidosis, whereas SUVmax showed no prognostic implications.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Shao G, Kaiser B, Gabriel M, et al. Prognostic Implications of Volume-based Quantitative 18F-FDG PET/CT Biomarkers in Pulmonary Sarcoidosis. Clin Nucl Med. 2025. PMID: 41499307. doi:10.1097/RLU.0000000000006212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。